| 名称 | Motixafortide TFA(664334-36-5,Free) |
| 描述 | Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ～1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. |
| 体外活性 | Treatment with Motixafortide induces the robust mobilization of AML blasts from the BM. In addition, AML cells exposed to Motixafortide undergoes differentiation. Motixafortide induces the apoptosis of AML cells in vitro, which is mediated by the up-regulation of miR-15a/miR-16-1, resulting in down-regulation of the target genes BCL-2, MCL-1 and cyclin-D1. Overexpression of miR-15a/miR-16-1 directly induces leukemic cell death. Motixafortide-induced apoptosis is also mediated by the inhibition of survival signals via the AKT/ERK pathways. |
| 体内活性 | Motixafortide also synergizes with FLT3 inhibitors to induce AML cell death. Importantly, this combined treatment prolongs the survival of tumor-bearing mice and reduces minimal residual disease in vivo. |
| 存储条件 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | H2O : 100 mg/mL (46.31 mM), Sonication is recommended.
DMSO : 100 mg/mL (46.31 mM)
|
| 关键字 | Motixafortide TFA(664334 36 5,Free) | Motixafortide TFA(664334-36-5,Free) | Motixafortide TFA(664334365,Free) |
| 相关产品 | Tannic acid | Nicotinamide N-oxide |
| 相关库 | 细胞因子抑制剂库 | 趋化因子抑制剂库 | 多肽分子库 | NO PAINS 化合物库 | PPI抑制剂库 |
United States
